Avoid in individuals with a known allergy or hypersensitivity to arabinoxylan, mushrooms, yeast or rice bran.
Users of MGN-3 (BioBran®) should be aware of other constituents (cornstarch, dextrin, tricalcium phosphate, silicon dioxide). Patients with allergies to other constituents should not take MGN-3.
In general, safety data are lacking; however, arabinoxylan has been well tolerated in clinical practice in Japan at recommended doses for short periods of time.
Arabinoxylan products like MGN-3 (BioBran®) may contain high calcium and phosphorus levels, which may be harmful for patients with compromised renal (kidney) function.
Patients with diabetes and those taking blood sugar lowering medications should use arabinoylan cautiously because arabinoxylan may lower blood sugar.
Arabinoxylan is not recommended in pregnant or breastfeeding women due to a lack of available scientific evidence.
MGN-3 may be safely and advantageously used with chemotherapy and radiation to increase the cytotoxic effect of the therapy and to decrease adverse side effects. A qualified healthcare practitioner, including a pharmacist, should be consulted before combining arabinoxylan with other medications or therapies.
Arabinoxylan may possess immuno-stimulant properties, and could theoretically interact with other drugs that alter the immune system. Caution is advised.
Preparations of MGN-3 (BioBran®) arabinoxylan product contain unclear amounts of calcium and phosphorous.
Arabinoxylan may reduce blood sugar levels, and could theoretically interact with blood sugar lowering herbs and supplements.
Arabinoxylan may possess immuno-stimulant properties, and could theoretically interact with other herbs and supplements that alter the immune system. Caution is advised.
This information is based on a professional level monograph edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Samuel D. Benjamin, M.D (Humana Inc.); Rebecca Bramwell, PharmD (Massachusetts College of Pharmacy); Nicole Giese, MS (Natural Standard Research Collaboration); Ernest Hawkins, BSPharm, RPh (Natural Standard Research Collaboration); Erica Rusie, PharmD (Nova Southeastern University); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Verda Tunaligil, MD, MPH (Harvard School of Public Health); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Wendy Weissner, BA (Natural Standard Research Collaboration); Jen Woods, BS (Northeastern University).